diagnostics system News
-
Quidel to Present at 40th Annual J.P. Morgan Healthcare Conference
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference to be held virtually on Wednesday, January 12, 2022. Douglas Bryant, president and chief executive officer, will present that day at 1:30 p.m. Eastern time (10:30 ...
-
Quidel to Hold Fiscal Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 17th, 2022
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal fourth quarter and full year 2021 financial results after market close on Thursday, February 17, 2022. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial ...
-
Moody´s upgrades outlook for Dürr rating
Stuttgart - Moody´s has upgraded the outlook for Dürr AG´s corporate credit rating from 'negative' to 'stable'. Dürr AG´s corporate credit rating continues to stand at 'B2'. Moody´s caused the upgrade with Dürr´s steady improvements in operating performance over recent months. The outlook change also reflects Moody´s expectation that Dürr will record further improvements not only in operating ...
-
Specific Diagnostics Announces the Creation of a European Warehouse and Servicing Center
Specific Diagnostics today announces the opening of its European warehouse and servicing center in Amsterdam, Netherlands, to support its growing European operations. Working with global integrated logistics leader Crane Worldwide Logistics, Specific and its European subsidiary Specific Diagnostics Europe, Ltd., will warehouse Reveal® instruments and consumables in the Amsterdam facility. The ...
-
Quidel’s Antigen Tests Detect the Omicron Variant
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement from Douglas Bryant, Quidel’s President and CEO, regarding Quidel’s ongoing efforts to evaluate COVID-19 mutations and confirm that its antigen tests continue to detect COVID-19 ...
-
NEW: NOVEOS Inhalant-Screen (SX01) using molecular allergology
In 2018, HYCOR introduced the NOVEOS system with a revolutionary 4μL sample size that effectively eliminated common interferences (CCD and biotin) present in other mainstream allergy diagnostic systems. In 2021, HYCOR has now added to that groundbreaking step forward by introducing the NOVEOS Screen Inhalant mix that makes use molecular allergology to improve clinical strategies for patient ...
-
Specific Diagnostics Announces that David Barreca, former GenMark Sales Leader, Joins Specific as
Specific Diagnostics today announced the appointment of David Barreca as Vice President of US Sales. David was a key member of GenMark’s sales leadership team, most recently a Senior Director managing a team of Account Executives that drove growth of the GenMark infectious disease diagnostics product, contributing the sales growth that led to GenMark’s acquisition by Roche Diagnostics ...
-
Former Genmark Senior Vice President Scott O’Brien Joins Specific Diagnostics as Chief Commercial Officer
Specific Diagnostics today announced the appointment of Scott O’Brien as its Chief Commercial Officer. Mr. O’Brien is an industry veteran with over 20 years in molecular and infectious disease diagnostics, the last 10 at GenMark where he held a range of commercial positions, most recently Senior Vice President Global Marketing and International Sales at GenMark Diagnostics, ...
-
Specific Diagnostics Commences US Clinical Trials for FDA 510(k) Clearance of its Reveal Rapid AST System
Specific Diagnostics announces today the commencement of its US clinical studies for the Reveal Rapid AST System for blood infection. Trials will entail 3 months of data collection followed by submission for FDA consideration of 510(k) clearance of the Reveal test. In Europe, where the Reveal is launched under CE-IVD registration, 11 studies across France and England comprising over 1,400 ...
-
Specific Diagnostics Announces the Formation of its US Commercial Team and Introduction of the Reveal Rapid AST System to the US Market
Specific Diagnostics today announced formation of its US commercial sales, service, support and marketing teams in anticipation of the launch of the Reveal Rapid AST System for blood infection samples. Following 11 studies across France and England comprising over 1,400 clinical positive blood culture samples, yielding overall accuracy of 97.8%, and in tandem with the commencement of clinical and ...
-
Brain Sentinel, Inc. Announces the Purchase of IctalCare A/S Assets
Brain Sentinel, Inc., a Texas company, has purchased the assets of IctalCare A/S, a Danish company. These assets include intellectual property, and a non-prescription, wearable device designed to monitor for seizure activity. "We are excited to add to our product line a small, wearable surface electromyography (sEMG) monitor that consumers may order and use without a prescription," said Mike ...
-
Vela Diagnostics Announces Development of New Test Kit for Detection of Wuhan Coronavirus
Vela Diagnostics has announced the development of the ViroKey SA201 2019-nCoV RT-PCR Test, a new test kit for the detection of the 2019 Novel Coronavirus (2019-nCoV), otherwise known as the Wuhan Coronavirus. The Wuhan Coronavirus was first identified in mid-December 2019 in Wuhan, China. Human-to-human transmission has been confirmed by China’s health ministry. According to Chinese health ...
-
Digital Diagnostics Named to the 2022 CB Insights’ Digital Health 150 List
Coralville, Iowa December 7, 2022 — Digital Diagnostics – a leading AI diagnostics company on a mission to transform global healthcare – is a recipient of CB Insights’ fourth-annual Digital Health 150. The list recognizes the 150 most promising private digital health companies of 2022. “From reimagining clinical care, to leveraging tech like AR/VR to improve ...
-
FDA Authorizes New Saliva Sample Collection Method for High-Throughput, Automated COVID-19 Testing System
Thermo Fisher Scientific, the world leader in serving science, today announced that it received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to run COVID-19 tests from saliva samples collected with the Spectrum Solutions SpectrumDNA SDNA-1000 collection device on the Amplitude Solution. SDNA saliva collection devices are self-contained systems that provide ...
-
Agilent Technologies Introduces Modular Real-Time PCR System with Precision Optics and Dependable Thermal Uniformity
Agilent Technologies Inc. (NYSE: A) today introduced the AriaMx System, the first instrument for real-time polymerase chain-reaction (PCR) that features easily-changeable optics cartridges for genotyping via high-resolution melt, gene-expression analysis, pathogen detection, and a variety of complex research applications. "Expanding functionality of this innovative system is as easy as replacing ...
-
Specific Diagnostics announces that Nathan Clark, former GenMark Sales Leader, joins Specific Diagnostics as Strategic Account Director, US East
Specific Diagnostics today announced the appointment of Nathan Clark as Strategic Account Director. Nathan was a key member of the GenMark sales leadership team, most recently as a sales manager for GenMark’s Northeast region, overseeing a team of 7 sales professionals and infectious disease specialists responsible for approximately $70M of revenue. Nathan was a critical part of the sales ...
-
Thermo Fisher Scientific Launches CE-IVD-Marked High Throughput COVID-19 Diagnostic Assay for Use On Its Automated Amplitude Platform
Thermo Fisher Scientific, the world leader in serving science, today launched its CE-IVD-Marked, Applied Biosystems TaqPath COVID–19 HT Kit that is compatible with the Amplitude platform. The high-throughput solution enables clinical and public health laboratories to efficiently test up to 8,000 COVID-19 samples a day with fewer staffing requirements and a reliable supply of kits, reagents ...
-
CEO Nick Traggis is working to scale manufacturing as the healthcare market demands faster point-of-care diagnostics.
Traggis started working with LightDeck Diagnostics founder Chris Myatt at a previous endeavor, Precision Photonics, a Boulder-based manufacturer of laser optics, in the early 2000s. Originally named MBio Diagnostics, LightDeck began as a “skunkworks effort” inside Precision. “I ended up taking over the reins there at Precision Photonics around the time Chris started focusing ...
-
Digital Diagnostics Extends Appreciation to CMS for Improving Access to Innovative, Validated Healthcare AI Designed to Eliminate Disparities and Drive Equity
Coralville, Iowa, November 2, 2021 – Digital Diagnostics commends the Centers for Medicare & Medicaid Services (CMS) for recognizing that FDA-cleared, rigorously validated healthcare autonomous artificial intelligence (AI) can address health care disparities and drive health equity. CMS’ CY 2022 Medicare Physician Fee Schedule (MPFS) and CY 2022 Outpatient Prospective Payment ...
-
Digital Diagnostics Partners with Rapidly Scaling Medicare Advantage Organization, ArchWell Health
CORALVILLE, IOWA July 26, 2022 – Digital Diagnostics is proud to announce a partnership with ArchWell Health to bring IDx-DR, the autonomous AI diagnostic system for the detection of diabetic retinopathy (DR) – including diabetic macular edema (DME) – to ArchWell Health centers across the United States. “ArchWell Health is committed to improving patient outcomes and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you